Fritz Offner
Overview
Explore the profile of Fritz Offner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
4807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Decruyenaere P, Giuili E, Verniers K, Anckaert J, De Grove K, Van der Linden M, et al.
Front Oncol
. 2023 Nov;
13:1221471.
PMID: 37954086
Introduction: Diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) are aggressive histological subtypes of non-Hodgkin's lymphoma. Improved understanding of the underlying molecular pathogenesis has led to new...
12.
Clarisse D, Prekovic S, Vlummens P, Staessens E, Van Wesemael K, Thommis J, et al.
Cell Mol Life Sci
. 2023 Aug;
80(9):249.
PMID: 37578563
The glucocorticoid receptor (GR) is a crucial drug target in multiple myeloma as its activation with glucocorticoids effectively triggers myeloma cell death. However, as high-dose glucocorticoids are also associated with...
13.
Decruyenaere P, Verniers K, Poma-Soto F, Van Dorpe J, Offner F, Vandesompele J
Lab Invest
. 2023 Apr;
103(2):100027.
PMID: 37039153
Archived formalin-fixed, paraffin-embedded (FFPE) tissue samples are being increasingly used in molecular cancer research. Compared with fresh-frozen tissue, the nucleic acid analysis of FFPE tissue is technically more challenging. This...
14.
Plesner T, Harrison S, Quach H, Lee C, Bryant A, Vangsted A, et al.
Clin Hematol Int
. 2023 Jan;
5(1):43-51.
PMID: 36656461
Introduction: This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-BCMA/CD16a bispecific antibody. Methods: RO7297089 was administered weekly by intravenous infusion to patients with...
15.
Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna K, Johnson R, et al.
EClinicalMedicine
. 2023 Jan;
56:101779.
PMID: 36618900
Background: This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible...
16.
Barr P, Owen C, Robak T, Tedeschi A, Bairey O, Burger J, et al.
Future Oncol
. 2023 Jan;
PMID: 36617990
What Is This Summary About?: This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original...
17.
Dickinson M, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al.
N Engl J Med
. 2022 Dec;
387(24):2220-2231.
PMID: 36507690
Background: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. Methods: In...
18.
Janssens A, Berneman Z, Offner F, Snauwaert S, Mineur P, Vanstraelen G, et al.
Clin Hematol Int
. 2022 Oct;
4(4):133-143.
PMID: 36227519
The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM) in Belgium....
19.
Vlummens P, Verhulst S, de Veirman K, Maes A, Menu E, Moreaux J, et al.
Front Cell Dev Biol
. 2022 Jun;
10:879057.
PMID: 35757005
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Here,...
20.
Petsophonsakul P, Pirmani A, De Brouwer E, Akand M, Botermans W, Van der Aa F, et al.
Stud Health Technol Inform
. 2022 May;
294:829-833.
PMID: 35612220
The complexity and heterogeneity of cancers leads to variable responses of patients to treatments and interventions. Developing models that accurately predict patient's care pathways using prognostic and predictive biomarkers is...